Zura Bio Submits Scleroderma Drug Protocol for FDA Phase 2 Study
Zura Bio, a clinical-stage immunology company, has submitted a Phase 2 study protocol to the FDA for tibulizumab. This...
Acquisitions AI in Clinical Trials Analysis Article Artificial Intelligence in Clinical Trials Clinical Research Clinical Trial Innovation Clinical Trial Management System Clinical Trial Patient Engagement Clinical Trial Payments Clinical Trial Quality Clinical Trial Risk Management Clinical Trials Clinical Trial Tech Conference Coverage CTMS Data Analysis Data Management DCT Decentralized Clinical Trials DHT Digital Health Technologies eClinical Tech News eCOA eConsent EDC Executive Interviews FDA FDA Guidance GCP ICH E6 Liver Clinical Trials News Oncology Opinion Pfizer Protocol RBQM RWD RWE Solid Tumors sponsor Stanford Thyroid Tufts CSDD
Zura Bio, a clinical-stage immunology company, has submitted a Phase 2 study protocol to the FDA for tibulizumab. This...
Lineage Cell Therapeutics announced its third quarter 2024 financial and operating results, highlighting progress in its allogeneic cell therapy...
Perspectum, a medical imaging technology company, has received a substantial research grant from the U.S. Food and Drug Administration...
A coalition of prominent cancer organizations, alongside Illinois lawmakers, is advocating for the Illinois Cancer Patients Bill of Rights....
The Global Healthy Living Foundation (GHLF) presented groundbreaking research at the 2024 American College of Rheumatology (ACR) Convergence in...
Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company focused on endocrinology and rheumatology, presented interim Phase 2 trial data for clofutriben...
KORU Medical Systems, Inc. reported strong third-quarter 2024 financial results and raised its full-year 2024 guidance for revenue, gross...
Quince Therapeutics, a late-stage biotechnology company focused on treating rare diseases, provided a pipeline update and financial results for...
Omeros Corporation recently announced its third-quarter 2024 financial results and provided updates on its clinical development programs. The company...
TAE Life Sciences (TLS), a prominent developer of boron neutron capture therapy (BNCT) technology and related boron target drugs,...